Previous close | 0.7900 |
Open | 0.8400 |
Bid | 0.7000 |
Ask | 0.8400 |
Strike | 10.00 |
Expiry date | 2024-07-19 |
Day's range | 0.6700 - 1.3000 |
Contract range | N/A |
Volume | |
Open interest | 440 |
Cassava Sciences (SAVA) is reportedly forming a committee to investigate two senior employees. This comes after a US probe into fraud and a Cassava researcher was indicted by a jury over alleged fabrication of Alzheimer's drug trial results. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
A federal indictment accuses a Cassava Sciences advisor of faking data to secure NIH grants. The company also faces shareholder suits.
AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university’s medical school as well as a former paid science advisor to Cassava Sciences. According to public court documents, Dr. Wang engaged in illegal behavior to defraud the go